PRINT THIS PAGE

In pivotal studies evaluating CIMZIA for treatment of moderately to severely active rheumatoid arthritis (RA), patients treated with CIMZIA experienced significant improvement in all ACR core measures of disease activity, including reduction in the total number of swollen and tender joint counts.1-3 These improvements were both rapid and sustained.1-3

Joint count data for the CIMZIA 200 mg every 2 weeks plus methotrexate (MTX) treatment group of RAPID 1 (52-week study) and for the CIMZIA 400 mg every 4 weeks group of FAST4WARD (24-week monotherapy study) are summarized below.


RAPID 1: Significant, sustained reduction of swollen and tender joints1

In RAPID 1, reduction in swollen and tender joint counts was evident at week 1 in patients receiving CIMZIA versus placebo.1 Swollen and tender joint counts continued to improve from week 4 to week 12 in patients receiving CIMZIA, with significant improvements versus placebo sustained at week 24 (-63.3% vs -9.6% placebo for swollen; -58.2% vs -9.0% placebo for tender) and week 52 (-65.7% vs -10.6% placebo for swollen; -61.6% vs
-10.1% placebo for tender).1,4 Similar results were seen in RAPID 2.2



Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.
Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers, including children, adolescents, and young adults. Acute and chronic cases of leukemia have also been reported.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.

FAST4WARD: Significant, sustained reduction of swollen and tender joints3

CIMZIA also produced significant improvement in the total number of swollen and tender joints in the FAST4WARD (monotherapy) trial.3 As in RAPID 1, these improvements were seen as early as week 1 and were sustained through week 24 (study conclusion).3

  • At week 1, swollen joint counts had decreased by 28% from baseline (vs 14% for placebo), and tender joint counts had decreased 33% (vs 16%)3,4
  • At week 12, swollen joint counts had decreased by 54% from baseline (vs 32% placebo), and tender joint counts had decreased 51% (vs 25%)4
  • At week 24, swollen joint counts were 55% lower than at baseline (vs 32% for placebo), and tender joint counts had decreased 54% (vs 26%)3,4


*P<.001. Placebo values for swollen joint count were -14% at week 1, -32% at week 12, and -32% at week 24. (Negative percentages indicate a decrease in swollen joint count.)
†P<.001. Placebo values for tender joint count were -16% at week 1, -25% at week 12, and -26% at week 24. (Negative percentages indicate a decrease in tender joint count.)

NEXT: Improved Patient-Reported Outcomes »